Cell One Partners Inc., a strategic consulting firm supporting cell and gene therapy (CGT) companies, and Center for Breakthrough Medicines (CBM), a cell and gene therapy CDMO, entered a strategic partnership to accelerate the development and commercialization of cell and gene therapies.
 
Cell One Partners provides its clients with virtual company creation and management for all aspects of drug development and commercialization. This partnership combines Cell One Partners’ strategic vision of enabling new company formation through virtual executive leadership and program management to accelerate assets and finally to market with CBM’s industry-leading technologies, capabilities, and massive capacity for development, testing, and manufacturing of therapies.
 
“Our unique model of creating and managing virtual companies for CGT asset owners allows them to accelerate their pathway to commercialization via our unparalleled network of cell and gene therapy leaders and innovators to support all aspects of the development, manufacturing, and commercialization continuum at about one-third of the management cost of setting up a traditional company with C-level executives,” said George S. Goldberger, Founder and Chief Executive Officer of Cell One Partners. “The Center for Breakthrough Medicines is a valuable asset to our clients as their integrated, end-to-end services, all located in a single complex, allow innovator companies to optimize their working capital and focus on driving the science toward commercialization.”
 
Through this strategic partnership with CBM, on track to be the world’s largest single CGT manufacturing site with more than 700,000 sq.-ft. of manufacturing and testing facilities, including 30-plus GMP suites, CGT asset owners have access to end-to-end services to support R&D, process development, and clinical and commercial manufacturing, including starting materials (plasmid and nucleic acid synthesis) and cell banking. 
 
“The missions of our two organizations are aligned – to advance cell and gene therapy research from idealization to commercialization in an effort to save lives,” said Jennifer Manning, SVP of Global Strategic Partnerships at CBM. “A strategic partnership with Cell One Partners provides CGT developers access to Cell One Partners’ virtual C-Suite executives and strategic advisors and access to CBM’s expansive capacity, breadth of CGT technologies, R&D, process development and GMP manufacturing expertise, allowing innovators to focus on research, extend cash runway, simplify a complex supply chain, and accelerate the development and manufacturing of their therapies.”